Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1306 to 1320 of 7707 results

  1. Obinutuzumab for untreated advanced follicular lymphoma (TA513)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults.

  2. Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)

    Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C in adults.

  3. Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal) (TA859)

    After discussion with Paion AG, NICE is unable to make a recommendation on angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock. The company did not make an evidence submission because of uncertainty about the number of people who would be eligible for treatment. We will review this decision if the company decides to make a submission.

    Sections for TA859

  4. Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)

    Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults.

  5. Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months after treatment with rituximab or a rituximab-containing regimen in adults.

  6. Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) (TA594)

    NICE is unable to make a recommendation about the use in the NHS of brentuximab vedotin (Adcetris) for untreated advanced Hodgkin lymphoma in adults because Takeda did not provide an evidence submission.

    Sections for TA594

  7. Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)

    Evidence-based recommendations on dacomitinib (Vizimpro) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.

  8. Risankizumab for treating moderate to severe plaque psoriasis (TA596)

    Evidence-based recommendations on risankizumab (Skyrizi) for treating moderate to severe plaque psoriasis in adults.

  9. Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA602)

    NICE is unable to make a recommendation on pomalidomide (Imnovid) with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma in adults because Celgene did not provide an evidence submission.

    Sections for TA602

  10. Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal) (TA603)

    NICE is unable to make a recommendation on lenalidomide (Revlimid) with bortezomib and dexamethasone for untreated multiple myeloma in adults because Celgene did not provide an evidence submission.

    Sections for TA603

  11. Idelalisib for treating refractory follicular lymphoma (TA604)

    Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.

  12. Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal) (TA608)

    NICE is unable to make a recommendation on ibrutinib (Imbruvica) with rituximab for treating Waldenstrom’s macroglobulinaemia in adults because Janssen did not provide an evidence submission.

    Sections for TA608

  13. Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) (TA609)

    NICE is unable to make a recommendation on ramucirumab (Cyramza) for treating unresectable hepatocellular carcinoma in adults who have had sorafenib, because Lilly did not provide an evidence submission.

    Sections for TA609

  14. Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)

    Evidence-based recommendations on pentosan polysulfate sodium (Elmiron) for bladder pain syndrome in adults.

  15. Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)

    Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome in people aged 2 years and older.